PCSK9 inhibitors could significantly lower LDL cholesterol levels, but without evidence of how many lives could be saved, increasing pharmaceutical costs via widespread use of the drugs cannot be justified, Dr. John Ioannidis of Stanford University wrote in a viewpoint article in the Journal of the American Medical Association. In a second viewpoint piece, Dr. Harlan Krumholz of Yale University wrote that shared decision-making is needed for lipid-lowering therapy but the decision should be made on the basis of risk reduction, not cholesterol levels.
Metabolically healthy adults who were overweight had a 26% higher risk of heart disease, compared with normal-weight adults, while those who were obese had a 28% higher risk, according to a study in the European Heart Journal. People with three or more heart risk factors had twice the likelihood of developing heart disease regardless of their weight, the study found.
A study in the journal Nutrients found gut dysbiosis is associated with hypertension via induced vasoconstriction, as well as to the progression of atherosclerosis through impaired cholesterol elimination or through the formation of atherosclerotic plaque.
A database analysis estimated 86% of more than 105,000 patients with cardiovascular disease could reduce their LDL cholesterol to less than 70 mg/dl just using statin intensification with ezetimibe added as needed. An estimated 14% would hit maximum levels of the oral treatments and need to move on to a proprotein convertase subtilisin/kexin type 9 inhibitor, according to the study in JAMA Cardiology.
UK researchers found that type 2 diabetes patients with poor medication adherence had a higher risk for cardiovascular disease than those with good medication adherence. The findings in Diabetes Care, based on a meta-analysis of eight observational studies involving 318,125 adult diabetes patients, also revealed an association between good medication adherence and reduced risks for all-cause mortality and hospitalization.
Showcase your original research or quality improvement projects as part of PCNA's 24th Annual Cardiovascular Nursing Symposium, April 4-7, 2018, in Baltimore. Deadline to submit is Nov. 1, 2017. Never submit your work before? Our meeting is a great place to get started. We have a complimentary webinar on writing strong abstracts, as well as abstract mentoring for authors pre-submission. Learn more.